Anticancer efficacy of unique pyridine-based tetraindoles

Area of Science:

• Medicinal Chemistry
• Oncology
• Pharmacology

Background:

• Previous studies showed tetraindole SK228 had moderate anticancer efficacy but low water solubility.
• This suggested pyridine-based tetraindole (PBT) analogs could improve bioavailability and efficacy.

Purpose of the Study:

• To synthesize and evaluate novel PBT analogs as potential anticancer agents.
• To investigate the mechanism of action and therapeutic efficacy of the most potent PBT analog.

Main Methods:

• Synthesis of pyridine-based tetraindole (PBT) analogs.
• In vitro antiproliferative assays against triple-negative breast cancer (TNBC) cell lines (MDA-MB-231, BT549).
• Cell cycle analysis, Western blotting for key proteins (cyclin B1, p-chk2, p-cdc2), apoptosis assays, and DNA repair assessment.
• In vivo efficacy studies in a human breast cancer xenograft model, including tumor growth and metastasis inhibition.

Main Results:

• Compound 3f (FCW81) exhibited the highest antiproliferative activity against TNBC cell lines.
• FCW81 induced G2/M cell cycle arrest, increased cyclin B1 and p-chk2, and decreased p-cdc2 levels.
• FCW81 caused DNA damage, induced apoptosis, and reduced DNA repair.
• FCW81 demonstrated significant therapeutic efficacy in vivo, inhibiting tumor growth and metastasis.

Conclusions:

• Novel pyridine-tetraindole based agents, particularly FCW81, show significant promise for TNBC therapy.
• FCW81's mechanism involves cell cycle arrest, apoptosis induction, and DNA repair inhibition.
• These findings support the development of FCW81 as a potential therapeutic agent for triple-negative breast cancer.